Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Modulation of RAB7A Protein Expression Determines Resistance to Cisplatin through Late Endocytic Pathway Impairment and Extracellular Vesicular Secretion.

Guerra F, Paiano A, Migoni D, Girolimetti G, Perrone AM, De Iaco P, Fanizzi FP, Gasparre G, Bucci C.

Cancers (Basel). 2019 Jan 8;11(1). pii: E52. doi: 10.3390/cancers11010052.

2.

Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells.

Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB.

Mol Cancer Ther. 2005 Oct;4(10):1595-604.

3.

P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.

Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, Melino G, Tsang BK.

Oncogene. 2011 Oct 13;30(41):4219-30. doi: 10.1038/onc.2011.134. Epub 2011 Apr 25.

4.

Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.

Li C, Ding H, Tian J, Wu L, Wang Y, Xing Y, Chen M.

Cell Physiol Biochem. 2016;39(1):242-52. doi: 10.1159/000445620. Epub 2016 Jun 24.

5.
6.

Rab7a regulates cell migration through Rac1 and vimentin.

Margiotta A, Progida C, Bakke O, Bucci C.

Biochim Biophys Acta Mol Cell Res. 2017 Feb;1864(2):367-381. doi: 10.1016/j.bbamcr.2016.11.020. Epub 2016 Nov 23.

7.

Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.

Ali AY, Kim JY, Pelletier JF, Vanderhyden BC, Bachvarov DR, Tsang BK.

Mol Carcinog. 2015 Nov;54(11):1301-14. doi: 10.1002/mc.22205. Epub 2014 Aug 23.

8.

Strain-Specific Altered Regulatory Response of Rab7a and Tau in Creutzfeldt-Jakob Disease and Alzheimer's Disease.

Zafar S, Younas N, Correia S, Shafiq M, Tahir W, Schmitz M, Ferrer I, Andréoletti O, Zerr I.

Mol Neurobiol. 2017 Jan;54(1):697-709. doi: 10.1007/s12035-016-9694-8. Epub 2016 Jan 14.

PMID:
26768426
9.

Down-regulation of miR-26b induces cisplatin resistance in nasopharyngeal carcinoma by repressing JAG1.

Shi L, Yin W, Zhang Z, Shi G.

FEBS Open Bio. 2016 Oct 24;6(12):1211-1219. doi: 10.1002/2211-5463.12135. eCollection 2016 Dec.

10.

Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer.

Kunii E, Oguri T, Kasai D, Ozasa H, Uemura T, Takakuwa O, Ohkubo H, Takemura M, Maeno K, Niimi A.

Cancer Chemother Pharmacol. 2015 May;75(5):985-91. doi: 10.1007/s00280-015-2723-x. Epub 2015 Mar 14.

PMID:
25772757
11.

Distinct expression, localization and function of two Rab7 proteins encoded by paralogous genes in a free-living model eukaryote.

Osińska M, Wiejak J, Wypych E, Bilski H, Bartosiewicz R, Wyroba E.

Acta Biochim Pol. 2011;58(4):597-607. Epub 2011 Oct 27.

12.

The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.

Yoshikawa K, Noguchi K, Nakano Y, Yamamura M, Takaoka K, Hashimoto-Tamaoki T, Kishimoto H.

Int J Oncol. 2015;46(6):2364-70. doi: 10.3892/ijo.2015.2948. Epub 2015 Apr 1.

PMID:
25846049
13.

Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.

Matsunaga T, Suzuki A, Kezuka C, Okumura N, Iguchi K, Inoue I, Soda M, Endo S, El-Kabbani O, Hara A, Ikari A.

Chem Biol Interact. 2016 Aug 25;256:142-53. doi: 10.1016/j.cbi.2016.07.008. Epub 2016 Jul 11.

PMID:
27417252
14.

FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein.

Song Y, Zhou X, Bai W, Ma X.

Tumour Biol. 2015 Jun;36(6):4197-202. doi: 10.1007/s13277-015-3056-4. Epub 2015 Jan 14.

PMID:
25586348
15.

Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin.

Kishimoto S, Kawazoe Y, Ikeno M, Saitoh M, Nakano Y, Nishi Y, Fukushima S, Takeuchi Y.

Cancer Chemother Pharmacol. 2006 Jan;57(1):84-90. Epub 2005 Nov 5.

PMID:
16044341
16.

Charcot-Marie-Tooth type 2B disease-causing RAB7A mutant proteins show altered interaction with the neuronal intermediate filament peripherin.

Cogli L, Progida C, Thomas CL, Spencer-Dene B, Donno C, Schiavo G, Bucci C.

Acta Neuropathol. 2013 Feb;125(2):257-72. doi: 10.1007/s00401-012-1063-8. Epub 2012 Nov 23.

17.

The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.

Park J, Ko YS, Yoon J, Kim MA, Park JW, Kim WH, Choi Y, Kim JH, Cheon Y, Lee BL.

Gastric Cancer. 2014;17(3):423-30. doi: 10.1007/s10120-013-0314-2. Epub 2013 Nov 8.

PMID:
24202965
18.

The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.

Juliachs M, Muñoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.

Clin Cancer Res. 2014 Feb 1;20(3):658-67. doi: 10.1158/1078-0432.CCR-13-1131. Epub 2013 Nov 25.

19.

Cell fate regulation by gelsolin in human gynecologic cancers.

Abedini MR, Wang PW, Huang YF, Cao M, Chou CY, Shieh DB, Tsang BK.

Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14442-7. doi: 10.1073/pnas.1401166111. Epub 2014 Sep 22. Erratum in: Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17684.

20.

Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.

Ahmed Z, Deyama Y, Yoshimura Y, Suzuki K.

Cancer Chemother Pharmacol. 2009 Mar;63(4):643-50. doi: 10.1007/s00280-008-0781-z. Epub 2008 Jun 11.

PMID:
18545997

Supplemental Content

Support Center